Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus MYTESI.
LOMANATE vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
100 mg orally twice daily
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal